Clinical trials: Cerebral Vascular Disorder
Acute Ischemic Stroke
Safety and Efficacy Evaluation of the Ceretrieve Device in the Treatment of AIS Patients
The main objective of this clinical trial is to evaluate of the safety \& efficacy of the Ceretrieve device within 24 hours post thrombectomy procedure.
- Trial name
- NCT06733246
- Testing
- Aspiration 0
- Where
- Germany
- Volunteers
- 132 people
- Sponsor
- Ceretrieve Ltd.
Acute Ischemic Stroke
Study Evaluating Single Ascending Doses Of ILS-920
This is a first-in-human study of ILS-920. This study will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ILS-920 after administration of ascending single…
- Trial name
- NCT00827190
- Testing
- ILS-920
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Femoral Artery Stenosis, Iliac Artery Stenosis
Retrospective Study of the Uni-Graft® K DV Patch in the Clinical Routine
Uni-Graft® K DV Patch is marketed in Europe since 1999 for reconstructive interventions of the deep femoral, femoral and iliac artery and was also indicated for carotid interventions until 01/2020.
- Conditions
- Femoral Artery Stenosis, Iliac Artery Stenosis, Carotid Artery Stenosis
- Trial name
- RESTUGPA (NCT05117515)
- Testing
- Vascular reconstruction
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Aesculap AG
Carotid Artery Disease, Carotid Artery Stenosis
The Gore SCAFFOLD Clinical Study
Evaluate the safety and efficacy of the GORE® Carotid Stent for the treatment of carotid artery stenosis in patients at increased risk for adverse events from carotid endarterectomy
- Trial name
- NCT01901874
- Testing
- Carotid Artery Stenting
- Where
- 2 sites in United States
- Volunteers
- 312 people
- Sponsor
- W.L.Gore & Associates
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Intracranial Aneurysm
pCONUS2 Treatment of Wide Neck Intracranial Aneurysms 2
To assess safety and efficacy of pCONUS2 for the treatment of wide neck bifurcation aneurysms.
- Trial name
- pToWin2 (NCT03273478)
- Testing
- Endovascular treatment of bifurcation aneurysm with pCONUS2
- Volunteers
- 100 people
- Sponsor
- Phenox GmbH
Chronic Aphasia
Effects of tDCS Versus HD-tDCS for Stroke Rehabilitation
The purpose of this study is to assess the changes in language processing of patients with chronic aphasia after receiving non-invasive brain stimulation.Previous research using traditional transcranial direct current stimulation…
- Trial name
- tDCS- Aphasia (NCT01651884)
- Testing
- HD-tDCS (Soterix), Transcranial Direct Current Stimulation (Neuroconn)
- Sponsor
- Soterix Medical
Stroke, Hemorrhagic Strokes
Evaluation of Clinical Effectiveness and Safety of Locaste 8F Guiding Catheter in Neurovascular Interventional Surgery
The Locaste 8F Delivery Catheter by Kai MedTech has been launched in China since 2022 and has been widely used clinically. It won the government tendering in many provinces in China in early 2024.
- Trial name
- NCT06917248
- Where
- 2 sites in China
- Volunteers
- 113 people
- Sponsor
- Keuro MedTech
Orthostatic Hypotension, Parkinson's Disease
A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease
This is a study to evaluate the effects of an investigational drug, Droxidopa, in participants with neurogenic orthostatic hypotension (NOH), associated with Parkinson's disease.
- Trial name
- 306A/306B (NCT01176240)
- Testing
- Droxidopa
- Where
- 60 sites in United States
- Volunteers
- 225 people
- Sponsor
- Chelsea Therapeutics
Acute Stroke
Evaluation of Neurosteer System in Stroke Patients
This is an observational study. Patients who fulfill all inclusion criteria and none of the exclusion criteria will be enrolled in the study, be neurologically evaluated and will go through a series of EEG recordings during their…
- Trial name
- NCT05524415
- Testing
- Neurosteer EEG recorder
- Where
- Israel
- Sponsor
- Neurosteer Ltd.
Cardiovascular Disease
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
The purpose of this study is to see whether subjects with gout who receive febuxostat or allopurinol for up to 9 years have a higher rate of serious heart and blood vessel complications (major cardiovascular events).
- Trial name
- CARES (NCT01101035)
- Testing
- Febuxostat, Allopurinol
- Where
- 203 sites in United States, Mexico
- Volunteers
- 6,198 people
- Sponsor
- Takeda
Stroke, Hemiparesis
Safety and Effectiveness of Cortical Stimulation in the Treatment of Stroke Patients With Upper Extremity Hemiparesis
The purpose of this study is to assess the safety and effectiveness of cortical stimulation delivered concurrent with rehabilitation activities to enhance motor recovery in patients suffering from hemiparesis affecting the upper…
- Trial name
- EVEREST (NCT00170716)
- Testing
- Cortical Stimulation and rehabilitation, Rehabilitation
- Where
- 21 sites in United States
- Volunteers
- 174 people
- Sponsor
- Northstar Neuroscience
PFO, PFO - Patent Foramen Ovale
Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study
The goal of this clinical trial is to test a new heart device called P3 Occluder System in patients who have a small opening between the upper chambers of the heart (called a Patent Foramen Ovale or PFO) and have experienced a…
- Conditions
- PFO, PFO - Patent Foramen Ovale, Cryptogenic Stroke, Patent Foramen Ovale
- Trial name
- PROTEA-PFO (NCT07172464)
- Testing
- Recross P3 Occluder (P3O) System
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Recross Cardio, Inc.
Stroke, Patent Foramen Ovale
AMPLATZER PFO Occluder Post Approval Study
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Setting.
- Trial name
- PFO PAS (NCT03309332)
- Testing
- AMPLATZER™ PFO Occluder
- Where
- 88 sites in United States, Canada and 5 more
- Volunteers
- 1,214 people
- Sponsor
- Abbott Medical Devices
Pediatrics, Muscle Spasticity
BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric upper limb spasticity.
- Conditions
- Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke
- Trial name
- NCT01603615
- Testing
- Botulinum Toxin Type A
- Where
- 48 sites in United States, Canada and 7 more
- Volunteers
- 220 people
- Sponsor
- Allergan
Acute Ischemic Stroke
Prospective Evaluation to Characterize the Real-World Performance of the EMBOVAC Aspiration Catheter
A post-market study evaluating the EMBOVAC Aspiration Catheter in acute ischemic stroke patients with confirmed intracranial large vessel occlusion.
- Trial name
- PERFECT (NCT04531904)
- Testing
- EMBOVAC Aspiration Catheter
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 102 people
- Sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.
Atherosclerotic Disease, Carotid
SmartRisk Stroke Prediction by MRI of Carotid Disease
Atherosclerotic plaque at the carotid artery bifurcation is a major source of stroke. The purpose of this investigation is to determine the ability of the SmartRisk software module to predict stroke or stroke-related events due…
- Trial name
- SmartRisk (NCT00860184)
- Where
- 15 sites in United States
- Volunteers
- 300 people
- Sponsor
- VPDiagnostics
Intracranial Aneurysm
Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation
To assess safety and efficacy of p64 MW HPC Flow Modulation Device under single antiplatelet therapy compared to p64 MW Flow Modulation Device under dual antiplatelet therapy.
- Trial name
- COATING (NCT04870047)
- Testing
- Endovascular treatment of unruptured aneurysms with p64 MW HPC Flow Modulation Device
- Where
- 18 sites in France, Germany and 5 more
- Volunteers
- 171 people
- Sponsor
- Phenox GmbH
Extracranial Carotid Artery Disease, TCAR
Real-World Treatment of Extracranial Carotid Artery Disease With the ENROUTE™ Transcarotid Neuroprotection System
The ENTRUST registry's objective is to collect real-world data (RWD) and health economic data on the ENROUTE™ Transcarotid Neuroprotection System (ENROUTE™ Transcarotid NPS), including populations in which outcomes of…
- Conditions
- Extracranial Carotid Artery Disease, TCAR, Transcarotid Artery Revascularization
- Trial name
- ENTRUST (NCT07455747)
- Testing
- Use of ENROUTE™ Transcarotid Neuroprotection System in conjunction with any commercially available Boston Scientific stent marketed for treatment of carotid artery disease
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- Boston Scientific Corporation
Spontaneous Subarachnoid Hemorrhage
A New Minimal-invasive Brain Tissue Probe Applying Near Infrared Spectroscopy
To assess the feasibility of a new brain tissue probe for multi-parameter neuromonitoring (NeMo Probe) and the accuracy of measurement values.
- Trial name
- NCT01801306
- Testing
- NeMo Probe
- Where
- Germany
- Volunteers
- 3 people
- Sponsor
- NeMoDevices AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.